<DOC>
	<DOCNO>NCT01228396</DOCNO>
	<brief_summary>Patients mark bladder dysfunction result secondary progressive multiple sclerosis recruit receive AIMSPRO placebo subcutaneous injection , double-blind crossover study .</brief_summary>
	<brief_title>AIMSPRO Treatment Bladder Dysfunction Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description>Treatment period 4 week ' duration separate 6 week wash-out phase . After 14 week randomise therapy 38 week period `` open-label '' AIMSPRO treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>M / F age 18 year old . Patients childbearing potential must use adequate birth control measure duration study 6 month receive last injection AIMSPRO . Clinically definite SPMS . Ambulant , walk aid allow . No one relapse within last 12 month relapse within last 6 month . Urinary frequency least 8 time per 24hours . Urinary urgency without urge incontinence . MRI brain spinal cord abnormality consistent MS . Screening laboratory test result must meet following criterion : Haemoglobin &gt; 9.5 g/dL WBC &gt; 3.5 x 109/L Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Baseline AST , alkaline phosphatase , Thyroid function , Serum Electrophoresis level must within normal range . Able adhere study visit schedule protocol requirement Capable give write informed consent . Acute symptomatic urinary infection . Taking DDAVP antimuscarinic agent . Full time wheelchair user . Immunosuppressant drug therapy kind last 3 month . Relapse within last 6 month . No clear progression disability last 12 month . Coexistent medical condition preclude participation , include history severe allergic reaction . Pregnant lactate woman woman plan pregnancy within 12 month screen ( i.e. , approximately 6 month follow last injection ) . Receipt investigational drug within 30 day prior screen within 5 halflives investigational agent , whichever longer . Treatment therapeutic agent target reduce TNF ( e.g. , infliximab , pentoxifylline , thalidomide , etanercept , etc . ) within 3 month screen . Previous administration AIMSPRO . Ongoing corticosteroid therapy corticosteroid within previous 3 month . History know allergy animal protein , tuberculosis . Serious infection ( pneumonia pyelonephritis ) previous 3 month . Less serious infection acute upper respiratory tract infection simple urinary tract infection , follow conclusion treat , appropriate , prior inclusion . Patients opportunistic infection within previous 6 month . Established malignant disease , renal , hepatic , haematologic , gastrointestinal , endocrine , pulmonary , cardiac disease . Significant neurological disorder . Presence transplant organ , exception corneal transplant &gt; 3 month prior screen . Lymphoproliferative disease include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location ( nodes posterior triangle neck , infraclavicular , epitrochlear , periaortic area ) , splenomegaly . Recent clinically significant substance abuse ( drug alcohol ) . Poor tolerability venipuncture . Investigational drug drug target reduce TNF allow participation study . Patients permit receive immunosuppressive treatment study . The exception patient 's treat neurologist determines course steroid therapy , oral intravenous , required view sufficiently disable relapse MS. Immunosuppressive therapy within month prior entry study . Taking licensed anticonvulsant medication lamotrigine antiarrhythmic drug flecainide , potent sodium channel block agent . Unable fill criterion relate bladder dysfunction status . Unable give write informed consent . Use intermittent indwell urinary catheter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>bladder</keyword>
	<keyword>optic neuritis</keyword>
	<keyword>secondary progressive multiple sclerosis</keyword>
	<keyword>AIMSPRO</keyword>
	<keyword>hyperimmune caprine serum</keyword>
	<keyword>hyperimmune goat serum</keyword>
</DOC>